Global Breast Cancer Metastatic Market – Industry Trends and Forecast to 2029

Global Breast Cancer Metastatic Market, By Treatment Type (ChemotherapyTargeted Therapy, Immunotherapy, Hormone Therapy, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.

Breast Cancer Metastatic Market Analysis and Size

The global breast cancer metastatic market is expected to witness significant growth during the forecast period. Breast cancer is the second most common cancer in the world and is the most common cancer in women globally. Generally, metastatic breast cancer may be detected months or years post the advanced or early detection and treatment of breast cancer such as stages 1, 2, or 3. Chemotherapy and radiation therapy are the most commonly diagnosed therapies used to cure metastatic breast cancer. The endlessly improving healthcare infrastructure, along with the increase in disposable incomes of people in Asia-Pacific region is expected to make the market grow in the forecast period. COVID-19 also had a major impact on the market growth.

Data Bridge Market Research analyses a growth rate in the global breast cancer metastatic market  in the forecast period 2022-2029. The expected CAGR of global breast cancer metastatic market  is tend to be around 10.40% in the mentioned forecast period. The market was valued at USD 17.10 billion in 2021, and it would grow upto USD 37.74 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Breast Cancer Metastatic Market Scope and Segmentation

Market Definition

Breast cancer metastatic is also known as stage IV or advanced breast cancer and is a non-specific type of breast cancer wherein the cancer spread beyond the breast such as bone and nearby lymph nodes. Metastatic breast cancer is also termed as distant recurrence. It is considered as breast cancer and treated as the same. Early detection result in desired outcomes including increased survival rate, number of treatment options, and improved quality of life. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period.

Global Breast Cancer Metastatic Market Dynamics

Drivers

• Increase in Breast Cancer

According to breastcancer.org, in 2022, it is projected that almost 30% of the newly discovered cancer cases in women get diagnosed with breast cancer. Additionally, as of 2021, breast cancer was the most widespread type of cancer worldwide, accounting for around 12% of all new cancer cases. Furthermore, the widespread R&D activities to achieve successful therapeutic for this disease and the growing number of patients with breast cancer are boosting the market growth exponentially.

• Rising Demand of Chemotherapy

According to Cancer World publication magazine reports, the number of patients requiring first-line chemotherapy was around 9.8 million in 2018 and is projected to reach 15 million by the end of 2040. Furthermore, the total number of patients requiring first-line chemotherapy is more possibly to rise by 53%. The survival rate by 2040 is expected to be 67%. Thus, this boosts the market growth.

Opportunities

• Growing Demand of Hospitals

The increasing number of hospitals in highly developing countries and the huge availability of numerous medical treatment equipment and drugs led to the huge demand of the hospital segment. According to AHRQ, there were about 2.8 million cancer-related adult nonmaternal hospitalizations. Among these cases, around 1.0 million stays had cancer as the principal diagnosis and comprises of an total cost of about USD 23.0 billion, accounting for 6.2 % of the total adult nonmaternal inpatient hospital costs. Thus, this huge demand is creating much opportunities for the market growth.

• Higher Indulgence of Immunotherapy

The segment of immunotherapy is projected to gain further attraction during the forecast period. Immunotherapeutics tend to have less adverse effects when compared to chemotherapeutics. Non-specificity, toxic side effects, and development of resistance associated with chemotherapy are most likely to suppress the growth of chemotherapeutics and boost the adoption of immunotherapeutics and other targeted treatments. This creates more opportunity in the market.

Restraints/Challenges

• Lack of Skilled Professionals

Lack of trained professionals who are not aware of the appropriate treatment methods for this disease could restrain the growth of the global breast cancer metastatic market  over a forecast period.

• Late Stage Trials and Drug Approvals

The halt of late-stage clinical trials and long wait for FDA approvals for novel drugs to treat metstatic breast cancer may also cause major difficulty to the growth of this market in the coming years.

This global breast cancer metastatic market  report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global breast cancer metastatic market  contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments:

• On 27th April 2022, AstraZeneca and Daiichi Sankyo's Enhertu were granted Breakthrough Therapy Designation (BTD) in the U.S. to cure adult patients with unresectable or metastatic HER2-low breast cancer who were previously treated with systemic therapy in the metastatic setting.
• On 13th October 2021, a group of Canadian researchers at Sunnybrook Health Sciences Centre successfully demonstrated the magnetic resonance (MR)-guided focused ultrasound that can be used to carefully conduct the antibody therapeutic treatment to breast cancer that has been already spread to the brain.
• On 7th April 2021, sacituzumab govitecan successfully received the FDA approval to treat metastatic triple-negative breast cancer patients who have already undergone two or more prior systemic treatments, out of which at least one was for metastatic illness. On the other hand, sacituzumab govitecan also got approval in April 2020 for the patients with mTNBC who previously underwent at least two treatments for metastatic disorders.

Global Breast Cancer Metastatic Market Scope

The global breast cancer metastatic market  is segmented on the basis of treatment type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment Type

• Immunotherapy
• Targeted Therapy
• Chemotherapy
• Hormone Therapy
• Others

Route of Administration

• Oral
• Parenteral

End-Users

• Hospitals
• Homecare
• Speciality Centres
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Breast Cancer Metastatic Market Regional Analysis/Insights

The global breast cancer metastatic market  is analysed and market size insights and trends are provided by treatment type, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global breast cancer metastatic market  report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to have the highest market growth due to the rise cases of HER2-positive breast cancer and favorable government policies as well as advanced healthcare facilities.

Asia-Pacific dominates the market due to the increase in government initiatives and rapidly increasing disposable income.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Breast Cancer Metastatic Market Share Analysis

The global breast cancer metastatic market  competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global breast cancer metastatic market.

Key players operating in the global breast cancer metastatic market include:

• Johnson & Johnson Private Limited (U.S.)
• Cipla Inc. (U.S.)
• Abbott (U.S.)
• AbbVie Inc. (U.S.)
• Merck KGaA (Germany)
• Sun Pharmaceutical Industries Ltd. (India)
• Aurobindo Pharma (India)
• Lupin (India)
• Hikma Pharmaceuticals PLC (U.K.)
• Amneal Pharmaceuticals LLC. (U.S.)
• Pfizer Inc (U.S.)
• Mylan N.V. (U.S.)
• Novartis AG (Switzerland)
• Bristol-Myers Squibb Company (U.S.)
• GlaxoSmithKline plc. (U.K.)
• Bayer AG (Germany)